+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens



Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens



Current Opinion in Drug Discovery and Development 3(1): 30-41



New chemical entities (NCEs) are abandoned in development primarily because of insufficient efficacy, safety issues and for economic reasons. Since efficacy and safety deficiencies are related in part to pharmacokinetics (PK), uncovering PK defects as early in drug discovery as possible would be highly valuable in reducing NCE failures in preclinical and clinical development. In this review, a strategy is put forth to integrate drug metabolism/pharmacokinetics and toxicology functions into drug discovery. Compound optimization in early- and late-phase drug discovery is covered, emphasizing physicochemical properties, in vitro absorption, metabolism and in vivo animal PK methodologies, primarily from the period 1998 to 1999. The present study also illustrates the idea of sorting oral bioavailability data into high/intermediate/low categories based on combining high/low rank-ordered information from physicochemical properties and in vitro absorption, metabolism and serum binding assays. It is shown that by combining the results from solubility, stability, absorption and metabolism assays, the high/intermediate/low human oral bioavailability for a series of beta- blockers can be approximately predicted. This method has a high sample throughput and should be useful in rank-ordering the predicted oral bioavailability of large collections of compounds at the lead optimization step of drug discovery. These results are useful for selecting compounds for future in vitro/in vivo correlation modeling or in vivo animal testing. This type of approach will improve the decision making process of compound selection in drug discovery.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 052269203

Download citation: RISBibTeXText

PMID: 19649835


Related references

Compound Optimization in Early and Late Phase Drug Discovery: Acceptable Pharmacokinetic Properties Utilizing Combined Physicochemical, In Vitro and In Vivo Screens. Frontiers in Medicinal Chemistry - Online 1(1): 607-618, 2004

Drug selection in early drug development: screening for acceptable pharmacokinetic properties using combined in vitro and computational approaches. Current Opinion in Drug Discovery and Development 2(1): 42-48, 1999

The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery. Current Topics in Medicinal Chemistry 1(5): 353-366, 2002

The New Pre-Preclinical Paradigm: Compound Optimization in Early and Late Phase Drug Discovery. Current Topics in Medicinal Chemistry 1(5): 353-366, 2001

ADME optimization and toxicity assessment in early- and late-phase drug discovery. Current Topics in Medicinal Chemistry 9(11): 965-980, 2010

Adme Optimization and Toxicity Assessment in Early- and Late-Phase Drug Discovery. Current Topics in Medicinal Chemistry 9(11): 965-980, 2009

Safety, pharmacokinetic, and physicochemical studies in the early stage of drug discovery. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 127(3): 217-221, 2006

Peptide Optimization at the Drug Discovery-Development Interface: Tailoring of Physicochemical Properties Towards Specific Formulation Requirements. Journal of Pharmaceutical Sciences 2018, 2018

Discovery of 4-aryl-N-arylcarbonyl-2-aminothiazoles as Hec1/Nek2 inhibitors. Part I: optimization of in vitro potencies and pharmacokinetic properties. Journal of Medicinal Chemistry 57(10): 4098-4110, 2014

Prediction of pharmacokinetic properties using experimental approaches during early drug discovery. Current Opinion in Chemical Biology 5(4): 452-463, 2001

Strategy of Utilizing In Vitro and In Vivo Adme Tools for Lead Optimization and Drug Candidate Selection. Current Topics in Medicinal Chemistry 5(11): 1033-1038, 2005

Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection. Current Topics in Medicinal Chemistry 5(11): 1033-1038, 2005

Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates. Journal of Medicinal Chemistry 53(16): 5897-5905, 2010

Combining high-throughput pharmacokinetic screens at the hits-to-leads stage of drug discovery. Drug Discovery Today 5(12 Suppl 1): 70-76, 2001

Combining high-throughput pharmacokinetic screens at the hits-to-leads stage of drug discovery. Drug Discovery Today 5(12-Supp-S1): 70-76, 2000